An interpretation of the expert consensus on standards for the management of patients with primary mitochondrial disease from the Mitochondrial Medicine Society
GUO Yi, HONG Si-Qi, JIANG Li
Department of Neurology, Children's Hospital, Chongqing Medical University, Chongqing 400014, China
Abstract：Primary mitochondrial disease is the most common inborn error of metabolism and is highly heterogeneous in terms of clinical manifestations and inheritance pattern. It has high mortality and disability rates. Multiple systems are often involved in this disease, and it is necessary to perform comprehensive evaluation and multidisciplinary management. The Mitochondrial Medicine Society issued the standard for the management of patients with primary mitochondrial disease:consensus statements from the Mitochondrial Medicine Society in 2017. The statements provided recommendations based on such consensus to guide the management and care of patients. This article interprets and summarizes the screening of organs and systems commonly involved in primary mitochondrial disease and the management of patients according to the consensus.
GUO Yi,HONG Si-Qi,JIANG Li. An interpretation of the expert consensus on standards for the management of patients with primary mitochondrial disease from the Mitochondrial Medicine Society[J]. CJCP, 2018, 20(11): 887-892.
Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease:a consensus statement from the Mitochondrial Medicine Society[J]. Genet Med, 2015, 17(9):689-701.
[2]
Parikh S, Goldstein A, Karaa A, et al. Patient care standards for primary mitochondrial disease:a consensus statement from the Mitochondrial Medicine Society[J]. Genet Med, 2017, 19(12):107.
[3]
Turoff M, Linstone HA. The Delphi method:techniques and applications[M]. Massachusetts:Addison-Wesley Publishing Co., 1975:2-7.
[4]
Sue CM, Lipsett LJ, Crimmins DS, et al. Cochlear origin of hearing loss in MELAS syndrome[J]. Ann Neurol, 1998, 43:350-359.
[5]
Karim W, Wulfran B, Anthony B, et al. Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases[J]. Eur Heart J, 2015, 36(42):2886-2893.
[6]
El-Hattab AW, Scaglia F. Mitochondrial cardiomyopathies[J]. Front Cardiovasc Med, 2016, 3:25.
[7]
Bates MG, Bourke JP, Giordano C, et al. Cardiac involvement in mitochondrial DNA disease:clinical spectrum, diagnosis, and management[J]. Eur Heart J, 2012, 33(24):3023-3033.
[8]
Schaefer AM, Walker M, Turnbull DM, et al. Endocrine disorders in mitochondrial disease[J]. Mol Cell Endocrinol, 2013, 379(1-2):2-11.
[9]
Karaa A, Goldstein A. The spectrum of clinical presentation, diagnosis, and management of mitochondrial forms of diabetes[J]. Pediatr Diabetes, 2014, 16(1):1-9.
[10]
El-Hattab AW, Emrick LT, Hsu JW, et al. Glucose metabolism derangements in adults with the MELAS m.3243A>G mutation[J]. Mitochondrion, 2014, 18:63-69.
[11]
Rahman S. Gastrointestinal and hepatic manifestations of mitochondrial disorders[J]. J Inherit Metab Dis, 2013, 36(4):659-673.
[12]
Cohen BH, Chinnery PF, Copeland WC. POLG-related disorders[M]//Pagon RA, Bird TD, Dolan CR, et al. Gene Reviews. Seattle:University of Washington, 1993::634-658.
[13]
Ng YS, Feeney C, Schaefer AM, et al. Pseudo-obstruction, stroke, and mitochondrial dysfunction:a lethal combination[J]. Ann Neurol, 2016, 80(5):686-692.
[14]
Rudolph CD, Hyman PE, Altschuler SM, et al. Diagnosis and treatment of chronic intestinal pseudo-obstruction in children:report of consensus workshop[J]. J Pediatr Gastroenterol Nutr, 1997, 24(1):102-112.
[15]
Walker MA, Slate N, Alejos A, et al. Predisposition to infection and SIRS in mitochondrial disorders:8 years' experience in an academic center[J]. J Allergy Clin Immunol Pract, 2014, 2(4):465-468.
[16]
Broomfield A, Sweeney MG, Woodward CE, et al. Paediatric single mitochondrial DNA deletion disorders:an overlapping spectrum of disease[J]. J Inherit Metab Dis, 2015, 38(3):445-457.
[17]
Rahman S, Hall AM. Mitochondrial disease-an important cause of end-stage renal failure[J]. Pediatr Nephrol, 2013, 28(3):357-361.
[18]
Emma F, Bertini E, Salviati L, et al. Renal involvement in mitochondrial cytopathies[J]. Pediatr Nephrol, 2012, 27(4):539-550.
[19]
Whittaker RG, Devine HE, Gorman GS, et al. Epilepsy in adults with mitochondrial disease:a cohort study[J]. Ann Neurol, 2015, 78(6):949-957.
[20]
Altmann J, Buchner B, Nadaj-Pakleza A, et al. Expanded phenotypic spectrum of the m.8344A>G "MERRF" mutation:data from the German mitoNET registry[J]. J Neurol, 2016, 263(5):961-972.
[21]
Tranchant C, Anheim M. Movement disorders in mitochondrial diseases[J]. Rev Neurol (Paris), 2016, 172:524-529.
[22]
Luigetti M, Sauchelli D, Primiano G, et al. Mitochondrial neuropathy:considerations on pathogenesis[J]. Eur J Neurol, 2016, 23(8):e55.
[23]
Menezes M P,Rahman S,Bhattacharya K,et al. Neurophysiological profile of peripheral neuropathy associated with childhood mitochondrial disease[J]. Mitochondrion, 2016, 30:162-167.
[24]
Gronlund M A,Honarvar A K,Andersson S,et al. Ophthalmological findings in children and young adults with genetically verified mitochondrial disease[J]. Br J Ophthalmol, 2010, 94(1):121-127.
[25]
Zhu CC, Traboulsi EI, Parikh S. Ophthalmological findings in 74 patients with mitochondrial disease[J]. Ophthalmic Genet, 2017, 38(1):67-69.
[26]
Wolfe LF, Joyce NC, McDonald CM, et al. Management of pulmonary complications in neuromuscular disease[J]. Phys Med Rehabil Clin N Am, 2012, 23:829-853.
[27]
Ramezani RJ, Stacpoole PW. Sleep disorders associated with primary mitochondrial diseases[J]. J Clin Sleep Med, 2014, 10(11):1233-1239.
[28]
Primiano G, Servidei S. Intestinal pseudo-obstruction in mitochondrial diseases[J]. Ann Neurol, 2017, 81(1):158-159.
[29]
Filler K, Lyon D, Bennett J, et al. Association of mitochondrial dysfunction and fatigue:A review of the literature[J]. BBA Clin, 2014, 1:12-23.
[30]
Luo Y, Yang X, Gao Y. Mitochondrial DNA response to high altitude:a new perspective on high-altitude adaptation[J]. Mitochondrial DNA, 2013, 24(3):313-319.
